New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...

I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...

ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc.

PRINCETON, N.J.--(BUSINESS WIRE)--Kanvas Biosciences, a full-stack spatial biology company, today announced results from a clinical trial of fecal microbiota transplantation (FMT) and anti-PD-1 ...

LC3-associated phagocytosis (LAP) is a specialized process for degrading dead cells, microbes or other particles. It plays a ...

Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and ...

What if bacteria held the keys to a part of our own immunity? For several years, some scientists have been exploring ...